entertainment -WSS

entertainment

author：focus 2025-10-02 23:45:06 - browse：5631

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： To bolster infectious disease surveillance, genomics powerhouses team up

explore

WSS

There's an unseen cost to disruptive road

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

'The View' co

CVS is on a mission to consolidate health care. Will it work?

A new deal aims to ramp up use of AI in rehab care decisions

Washington Commanders' Dan Snyder ordered to pay NFL $60M following investigation

Wikipedia

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Mass General, Mayo Clinic look to monetize custom

Affirmative action in medical school literally saved lives

New chief aims to remake Sanofi Genzyme

Medical leaders decry Supreme Court decision on affirmative action

The inclusion problem at the heart of rehabilitation research

State Dept. review finds Biden bears some blame for Afghanistan failures

TikTok, Instagram influencers need more rules for drug ads

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

There's an unseen cost to disruptive road

explore

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Pfizer's RSV vaccine recommended for approval in Europe

To bolster infectious disease surveillance, genomics powerhouses team up

Microsoft launches AI tool for clinical documentation through Epic

HPV vaccine, cervical cancer study delivers historic results

Why the advice to take all your antibiotics may be wrong

hotspot

explore

entertainment

entertainment